ELTX
Elicio Therapeutics Inc.
$9.29
+$0.04(+0.43%)
32
Overall
40
Value
20
Tech
36
Quality
Market Cap
$184.95M
Volume
80.85K
52W Range
$4.23 - $12.62
Target Price
$15.50
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $27.5M | $2.3M | -- | -- | ||
| Total Revenue | $28.3M | $2.3M | -- | -- | ||
| COST OF GOODS SOLD | ||||||
| Cost of Revenue | $433.0K | -- | -- | -- | ||
| GROSS PROFIT | ||||||
| Gross Profit | $27.9M | $2.3M | -- | -- | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $67.6M | $23.7M | $35.7M | $45.0M | ||
| Research & Development | $48.7M | $18.1M | $23.8M | $33.7M | ||
| Research Expense | $48.7M | $18.1M | $23.8M | $33.7M | ||
| Selling, General & Administrative | $18.5M | $5.6M | $11.9M | $11.3M | ||
| General & Administrative Expenses | $18.5M | $5.6M | $11.9M | $11.3M | ||
| Salaries & Wages | -- | -- | $1.2M | $1.5M | ||
| Depreciation & Amortization | $100.0K | $400.0K | $400.0K | $300.0K | ||
| Depreciation & Amortization | $100.0K | $400.0K | $400.0K | $300.0K | ||
| Amortization | -- | -- | -- | $75.0K | ||
| Other Operating Expenses | $433.0K | $1.2M | $1.5M | $1.5M | ||
| OPERATING INCOME | ||||||
| Operating income | $-39.3M | $-23.7M | $-35.7M | $-45.0M | ||
| EBITDA | $-50.0M | $-30.8M | $-44.9M | $-61.9M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $1.8M | $3.6M | $1.1M | -- | ||
| Intinc | -- | $65.0K | $373.0K | -- | ||
| Net Non-Operating Interest Income/Expense | $-1.8M | $-3.5M | $-686.0K | -- | ||
| Gain on Sale of Securities | -- | $-945.0K | $429.0K | -- | ||
| Other Income/Expense | $12.4M | $943.0K | $-1.0M | $3.9M | ||
| Other Special Charges | $-4.8M | $2.0K | $603.0K | $-3.9M | ||
| SPECIAL ITEMS | ||||||
| Restructring And Mn A Income | -- | $9.2M | -- | -- | ||
| Special Income Charges | -- | $-9.2M | -- | -- | ||
| Other Impairment Of Capital Assets | -- | $3.0M | -- | -- | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-52.7M | $-31.9M | $-46.1M | $-63.1M | ||
| Pre-Tax Income | $-54.6M | $-28.2M | $-34.5M | $-48.7M | ||
| INCOME TAX | ||||||
| Tax Provision | $-5.5M | $-7.3M | $-10.9M | $-11.2M | ||
| NET INCOME | ||||||
| Net Income | $-54.6M | $-28.2M | $-35.2M | $-51.9M | ||
| Net Income (Continuing Operations) | $-54.6M | $-28.2M | $-35.2M | $-51.9M | ||
| Net Income (Discontinued Operations) | $-54.6M | $-28.2M | $-35.2M | $-51.9M | ||
| Net Income (Common Stockholders) | $-54.6M | $-28.2M | $-35.2M | $-51.9M | ||
| Normalized Income | $-60.0M | -- | -- | $-60.0M | ||
| TOTALS | ||||||
| Total Expenses | $68.1M | $23.7M | $35.7M | $45.0M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $2.8M | $3.0M | $5.1M | $12.2M | ||
| Average Shares Outstanding (Diluted) | $2.8M | $3.0M | $5.1M | $12.2M | ||
| Shares Outstanding | $30.0M | $30.1M | $10.2M | $16.0M | ||
| Basic EPS | $-19.3 | $-12.9 | $-6.96 | $-4.25 | ||
| Basic EPS (Continuing Operations) | $-19.3 | $-12.9 | $-6.96 | $-4.25 | ||
| Diluted EPS | $-19.3 | $-12.9 | $-6.96 | $-4.25 | ||
| Diluted EPS (Continuing Operations) | $-19.3 | $-12.9 | $-6.96 | $-4.25 | ||
| OTHER METRICS | ||||||
| Earnings from equity interest | $-99.0K | $151.0K | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $-99.0K | $151.0K | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | $3.0K | ||
| Net Income Discontinuous Operations | -- | -- | -- | $3.0K | ||
| Other Gand A | $18.5M | $5.6M | $11.9M | $11.3M | ||
| Restruct | -- | $9.2M | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ELTX | $9.29 | +0.4% | 80.85K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Elicio Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW